ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease

Wednesday, May 17, 2017

Submitted by

Mark Ferguson

Source

Source Name: Annals of Thoracic Surgery

Source URL: http://dx.doi.org/10.1016/j.athoracsur.2016.11.061

Author(s)

Daniel P. O’Hair, Tanvir K. Bajwa, Stanley J. Chetcuti, G. Michael Deeb, Robert C. Stoler, Robert F. Hebeler, Brijeshwar Maini, Mubashir Mumtaz, Neal S. Kleiman, Michael J. Reardon, Shuzhen Li, David H. Adams, Daniel R. Watson, Steven J. Yakubov, Jeffrey J. Popma, George Petrossian

Using data from the CoreValve US Expanding Use Study, outcomes for patients with end stage renal disease (ESRD) undergoing TAVR were evaluated using an endpoint of all-cause mortality or major stoke at 1 year. Mortality at 1 year was 30%, and the stroke incidence was 2.1%. New permanent pacemaker need was 27%. The 1-year mortality appears increased compared to patients without ESRD.